|
BTG LICENSES HAEMOFILTRATION DEVICE PATENTS TO FRESENIUS MEDICAL CARE
22 April 2007 - BTG
| BTG plc, the medical innovations company, announces that it has granted Fresenius Medical Care AG & Co. KGaA a non-exclusive licence for the global rights to patents relating to a haemofiltration device for €4.5 million fully paid |
BTG plc, the medical innovations company, announces that it has granted Fresenius Medical Care AG & Co. KGaA a non-exclusive licence for the global rights to patents relating to a haemofiltration device for €4.5 million fully paid. Developed by researchers at Cincinnati Children's Hospital, the device improves the treatment of acute renal failure by enabling automated adjustments to be made during a haemofiltration session, reducing the possibility of human error and the need for supervision. Louise Makin, BTG's Chief Executive Officer, said: "We are pleased to have signed this agreement relating to the haemofiltration patents, and we are actively seeking additional licensees."
http://www.btgplc.com
About: BTG
BTG is an intellectual property and technology commercialisation company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realise value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialised important innovations, including Magnetic Resonance Imaging, Multilevel Cell Memory, Campath (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukaemia, and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd and BTG International Inc in the UK and USA, respectively. |
More News:
• For April 2007
• From BTG
• For Polymer OLED Devices
|
